Search Results
Oct 15, 2025, 18:02 ET RoboUP julkaisee Raccoon 2 SE:n: Pienten nurmikoiden helppokäyttöisimmän robottiruohonleikkurin, joka julkaistaan Kickstarterissa
vuosien ajan, tiimi tajusi, että pienet puutarhan omistajat kohtaavat omat haasteensa. Kiireinen elämäntapa jättää vähän aikaa nurmikon hoitoon, ja suurin osa markkinoilla olevista robottiruohonleikkureista on liian suuria ja liian kalliita pienille pihoille, jolloin he pysyttelevät manuaalisessa leikkaamisessa.
More news about: RoboUp
Oct 13, 2025, 02:15 ET Inwave ostaa Swedish Gatewayn ja nopeuttaa kansainvälistä laajentumista vähittäiskaupan alalla
Tämä siirto on osa Inwaven kansainvälistymisstrategiaa. Inwave vie jo 40 prosenttia laitteistostaan ja se on maailmanlaajuisesti tunnustettu asiantuntemuksestaan ja aloittaa
More news about: Inwave
Oct 09, 2025, 08:00 ET Apnimed to Participate in the 5th Annual Needham Private Biotech and MedTech Company Virtual 1x1 Forum
diseases. We believe the introduction of simple, once-nightly oral drugs may dramatically expand diagnosis and the reach of treatment for people with OSA. OSA, like other common chronic diseases such as diabetes or hypertension, would benefit from having multiple drugs with differing mechanisms to more fully
More news about: Apnimed, Inc.
Oct 07, 2025, 08:00 ET Apnimed Announces Acceptance of Two Late-breaking Presentations and a Core Interactive Session at the CHEST Annual Meeting Highlighting New Positive AD109 Phase 3 Data and the Current Unmet Need in Obstructive Sleep Apnea
trials of AD109, Apnimed's lead investigational once-daily oral therapy for OSA, alongside insights into the burden and unmet need of OSA, including results from the SHINE survey of US adults highlighting the negative impact of OSA on work productivity.
More news about: Apnimed, Inc.
Oct 03, 2025, 11:27 ET UtilityInnovation Group nimittää Jon Rodriguezin energiakeskusten johtajaksi johtamaan datakeskusten virtaratkaisuja
Energiakeskusten johtajana Rodriguez johtaa UIG:n pyrkimyksiä laajentaa alan johtavaa kokemusta ja tarjota ohjelmallisia ratkaisuja. Keskeinen osa UIG:n kehittynyttä energiatarjontaa on sen Energy Storage for Resiliency (ESR)® ja GridSure®-alusta. ESR® parantaa energiakeskusten
More news about: UtilityInnovation Group
Oct 02, 2025, 15:06 ET GAC lanseeraa AION V:n Suomessa ja laajentaa läsnäoloaan Euroopan sähköautomarkkinoilla.
AION V:n tulo Suomeen on keskeinen osa GAC-yhtiön yleiseurooppalaista strategiaa, joka nopeutui sen jälkeen, kun GAC ja Inchcape allekirjoittivat maailmanlaajuisen kumppanuussopimuksen Pariisin
More news about: GAC
Sep 29, 2025, 06:30 ET Brain Corp and Driveline Launch ShelfOptix™: The First Fully Managed, Robot-Powered Shelf Intelligence Service
and Harveys Supermarket. In the initial phase, the pilots are focused on helping retailers gain a better understanding of their on-shelf availability (OSA), Direct Store Distribution (DSD) execution, and compliance performance. "You can't fix what you can't see, and in retail, that
More news about: Brain Corp
Sep 19, 2025, 11:01 ET Sleep Aids Market to Hit US$ 118.97 Billion by 2033, Growing at 7.8% CAGR - DataM Intelligence
Singapore. The new device is equipped with a suite of advanced features designed to simplify the treatment and management of obstructive sleep apnea (OSA), a condition characterised by repeated pauses in breathing during sleep. Related Reports:
More news about: DataM Intelligence 4 Market Research LLP
Sep 19, 2025, 06:01 ET Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity;DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes;DREAMS-2:
More news about: Innovent Biologics
Sep 17, 2025, 18:01 ET Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
weight-related medical problems to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and
More news about: Eli Lilly and Company
Sep 17, 2025, 09:00 ET Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
obesity or overweight with at least one weight-related medical problem. It is also being studied as a potential treatment for obstructive sleep apnea (OSA) and hypertension in adults with obesity. About ACHIEVE-3 and ACHIEVE clinical trial program ACHIEVE-3 (NCT06045221) is a Phase
More news about: Eli Lilly and Company
Sep 15, 2025, 08:00 ET Apnimed to Participate in Upcoming September Investor Conferences
diseases. We believe the introduction of simple, once-nightly oral drugs may dramatically expand diagnosis and the reach of treatment for people with OSA. OSA, like other common chronic diseases such as diabetes or hypertension, would benefit from having multiple drugs with differing mechanisms to more fully
More news about: Apnimed, Inc.